ArticleEuropean radiology2023
MRI proton density fat fraction for estimation of tumor grade in steatotic hepatocellular carcinoma.
Article in European radiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 8 citations in OpenAlex.
- Preoperative MRI-derived fat fraction is linked to survival after liver transplantation for hepatocellular carcinoma.iLIVER · 2026Article
- Magnetic resonance imaging R2* mapping for evaluating Ki-67 proliferation index and cytokeratin 19 expression in solitary iron-sparing hepatocellular carcinoma: a retrospective single-center study.Quantitative imaging in medicine and surgery · 2026Article
- Qualitative and quantitative assessment of intratumoral fat using chemical-shift MRI for predicting histological grade of hepatocellular carcinoma.BMC medical imaging · 2026Article
- Intratumoral Proton Density Fat Fraction Predicts the Outcome of HAIC Combined With PD-1 Inhibitors in Advanced Hepatocellular Carcinoma.Cancer medicine · 2026Article
- GDPD5-CD55-EGFR competitive binding axis regulates radioresistance and lipid accumulation in rectal cancer.Cell death & disease · 2026Article
- High conversion rate and survival benefits of transarterial chemoembolization with targeted immunotherapy in initially unresectable hepatocellular carcinoma: efficacy, safety, and optimal patient selection.Wideochirurgia i inne techniki maloinwazyjne = Videosurgery and other miniinvasive techniques · 2025Article
- MRI proton density fat fraction for estimation of biological characteristics in hepatocellular carcinoma.BMC medical imaging · 2025Article
- [Study of a nomogram model of gadoxetate disodium-enhanced magnetic resonance imaging for the preoperative diagnosis of proliferative hepatocellular carcinoma and its value].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Article
- Hepatocellular Carcinoma: Imaging Advances in 2024 with a Focus on Magnetic Resonance Imaging.Current oncology (Toronto, Ont.) · 2025Review
- Predictive Value of IDEAL-IQ and DWI Imaging Biomarkers for P53 Mutations in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2025Article
- Diffuse and focal liver fat: advanced imaging techniques and diagnostic insights.Abdominal radiology (New York) · 2024Review
- Linearity and bias of proton density fat fraction across the full dynamic range of 0-100%: a multiplatform, multivendor phantom study using 1.5T and 3T MRI at two sites.Magma (New York, N.Y.) · 2024Article
- Imaging and prognostic characterization of fat-containing hepatocellular carcinoma subtypes.La Radiologia medica · 2024Article
- Fat fraction quantification with MRI estimates tumor proliferation of hepatocellular carcinoma.Frontiers in oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesImage-based detection of intralesional fat in focal liver lesions has been established in diagnostic guidelines as a feature indicative of hepatocellular carcinoma (HCC) and associated with a favorable prognosis. Given recent advances in MRI-based fat quantification techniques, we investigated a possible relationship between intralesional fat content and histologic tumor grade in steatotic HCCs.
methodsPatients with histopathologically confirmed HCC and prior MRI with proton density fat fraction (PDFF) mapping were retrospectively identified. Intralesional fat of HCCs was assessed using an ROI-based analysis and the median fat fraction of steatotic HCCs was compared between tumor grades G1-3 with non-parametric testing. ROC analysis was performed in case of statistically significant differences (p < 0.05). Subgroup analyses were conducted for patients with/without liver steatosis and with/without liver cirrhosis.
resultsA total of 57 patients with steatotic HCCs (62 lesions) were eligible for analysis. The median fat fraction was significantly higher for G1 lesions (median [interquartile range], 7.9% [6.0─10.7%]) than for G2 (4.4% [3.2─6.6%]; p = .001) and G3 lesions (4.7% [2.8─7.8%]; p = .036). PDFF was a good discriminator between G1 and G2/3 lesions (AUC .81; cut-off 5.8%, sensitivity 83%, specificity 68%) with comparable results in patients with liver cirrhosis. In patients with liver steatosis, intralesional fat content was higher than in the overall sample, with PDFF performing better in distinguishing between G1 and G2/3 lesions (AUC .92; cut-off 8.8%, sensitivity 83%, specificity 91%).
conclusionsQuantification of intralesional fat using MRI PDFF mapping allows distinction between well- and less-differentiated steatotic HCCs. CLINICAL RELEVANCE: PDFF mapping may help optimize precision medicine as a tool for tumor grade assessment in steatotic HCCs. Further investigation of intratumoral fat content as a potential prognostic indicator of treatment response is encouraged. KEY POINTS: • MRI proton density fat fraction mapping enables distinction between well- (G1) and less- (G2 and G3) differentiated steatotic hepatocellular carcinomas. • In a retrospective single-center study with 62 histologically proven steatotic hepatocellular carcinomas, G1 tumors showed a higher intralesional fat content than G2 and G3 tumors (7.9% vs. 4.4% and 4.7%; p = .004). • In liver steatosis, MRI proton density fat fraction mapping was an even better discriminator between G1 and G2/G3 steatotic hepatocellular carcinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.